Watch as we delve into the nuances of animal welfare legislation in North America, specifically addressing the needs of clients and suppliers in the pharmaceutical and biotech sectors.
Our discussions touch upon the defining regulatory mandates, industry best practices, and the overarching ethical directions that guide the treatment of animals within these industries. Coupled with expert opinions and thought leadership on North American compliance standards, we aim to shine a light on our crucial role in ensuring ethical standards aren’t just met – they are exceeded.
Whether you’re a professional aiming to broaden your knowledge, an organization looking to solidify its regulatory grasp, or simply an animal welfare advocate keen on learning more about our combined responsibility, this series certainly has something for everyone.
To access additional resources and handouts, please contact [email protected].
Head over to Part Two (Asia-Pacific) or Part Three (Europe) for more!
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Presenters
Senior Director
In Vivo and GLP Services
Scientist.com
Meaghan Loy is currently the Senior Director of In Vivo and GLP Services at Scientist.com, a research marketplace that enables researchers to access pre-qualified assessed animal model suppliers as well as hundreds of suppliers that provide in vitro models that can potentially replace or reduce the use of in vivo models. She joined Scientist.com in 2018 and is an expert in the use of COMPLi®, Scientist.com’s award winning platform that introduces a common, comprehensive process and supply agreement supporting access to pre-qualified assessed suppliers of in vivo and in vitro research models and provides animal welfare compliance coverage.
Executive Director
The 3Rs Collaborative
Dr. Megan LaFollette is Executive Director at The 3Rs Collaborative where she advances better science, for both people and animals. Her expertise includes a wide range of topics including animal welfare, human-animal interactions, compassion fatigue resiliency, and even microphysiological systems. She is committed to advancing widespread implementation of practical, impactful, and evidence-based 3Rs techniques: refinement, reduction, and replacement.
Director
Regulatory and Quality
Certis Oncology Solutions, Inc.
Diana Hornberger is the Director of Regulatory and Quality at Certis Oncology Solutions, Inc., a specialty CRO with expertise in human pre-clinical cancer modelling. With 17 years of experience, she has expertise in regulatory compliance, quality assurance and control, vivarium management, animal welfare, operations, and In Vivo model development.
Production Partner
Certis Oncology Solutions, Inc.
Certis is an AI-enabled precision oncology and translational science company. Our product is Oncology Intelligence®—highly predictive therapeutic response data derived from advanced models of cancer. We partner with oncology therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Using CertisAI™, our proprietary artificial intelligence/machine learning platform, and more clinically relevant, patient-derived tumor models, we bring certainty to lead candidate selection and help secure clear and compelling evidence of drug efficacy.
Additional Content From Certis Oncology Solutions, Inc.
Combination Therapy for Glioblastoma: A Personalized, AI-Driven Approach
Discover how AI-driven models and patient-derived xenografts are advancing personalized combination therapies for glioblastoma.
Artificial Intelligence in Preclinical Research: Pathology, Biospecimens, and Model Selection
Learn how AI is advancing preclinical research through quantitative pathology, curated biospecimen data, and intelligent tumor model selection in this expert-led webinar.
Leveraging Genomic, Preclinical, and Drug Response Data in the Age of AI
Join Dr. Michael Boice from Certis Oncology for a discussion and demonstration of how artificial intelligence can improve preclinical decision-making in cancer research.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.